You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 430 results
 
  • Record 1 TO 430

  1. Dendritic Cell Subset for Enhanced Cancer Vaccine

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Tumor antigen primed dendritic cells (DCs) are under widespread clinical evaluation for immunotherapy of multiple forms of cancer. Emerging evidence suggests that DCs are fundamental regulators of the immune response

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  2. Bioreactor for Enhanced T-cell Based Therapy of Melanoma

    SBC: Aastrom Biosciences, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Malignant melanoma is a significant and deadly form of cancer worldwide. Emerging evidence has shown that melanoma cells express tumor-associated antigens that are specifically recognized by the immune system. Melanom

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  3. Targeted Prodrug Therapy of Liver Cancers

    SBC: ACCLAIM BIOTECHNOLOGY            Topic: N/A

    DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) and colorectal cancer (CRC) are among the most common and deadly malignancy worldwide. CRC is the second leading cause of cancer-related death in the USA, mostly due to metastases to the

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  4. Catheter to thermally classify atherosclerotic plaque

    SBC: ACCUMED SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this study will be to detect the prevalence and prognostic value of plaque temperature heterogeneity in diabetic patients undergoing stent implantation. The objective is to develop and commercialize a

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health

  5. Catheter to thermally classify atherosclerotic plaque

    SBC: ACCUMED SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this study will be to detect the prevalence and prognostic value of plaque temperature heterogeneity in diabetic patients undergoing stent implantation. The objective is to develop and commercialize an intraluminal Thermal Sensing System (TSS) for taking surface temperature measurements of atherosclerotic plaque lesions within the walls of cor ...

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  6. Novel A2A Adenosine Agonists in Vascular Protection

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health

  7. Antagonists of A2B Receptors Improve Insulin Sensitivity

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health

  8. A2A Adenosine Receptor Agonist for the Treatment of IBD

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosin

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  9. Rare Cell Isolation for Morphological & Molecular Study

    SBC: Adeptas, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): A first step in the elucidation of the genetic changes and molecular profiles associated with the development of cancer is the isolation of rare tumor cells from a background of millions of normal cells, or the fracti

    SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health

  10. Small Molecule Blockers of B. anthracis Toxin

    SBC: Innovative Biologics Inc.            Topic: N/A

    DESCRIPTION (provided by investigator): Results from our SBIR Phase I project demonstrated that beta-cyclodextrin derivatives designed to block the trans-membrane channel formed by B. anthracis protective antigen (PA) can inhibit the cytotoxic effects

    SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government